Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management

The book discusses the use of neoadjuvant checkpoint inhibitors in localized genitourinary cancers,including bladder cancer,renal cell carcinoma,and prostate cancer. It highlights the mechanisms of response and resistance of cancer cells to immunotherapy and debates optimal trial design,clinical management,and biomarker use for patient selection.

Format: Paperback / softback
Length: 315 pages
Publication date: 05 January 2023
Publisher: Springer Nature Switzerland AG

The advent of immunotherapy has revolutionized the treatment of genitourinary malignancies, leading to the development of novel strategies for multidisciplinary management. This book aims to provide readers with a current overview of enrolling trials with immune-checkpoint inhibitors in the preoperative setting of localized bladder cancer, renal cell carcinoma, and prostate cancer.

Neoadjuvant checkpoint inhibitors have emerged as a promising treatment option for localized genitourinary cancers, offering the potential for improved outcomes and reduced treatment-related toxicities. In this book, we will explore the mechanisms of response and resistance of cancer cells to immunotherapy, as well as the optimal trial design of preoperative checkpoint inhibitors in GU tumors.

Optimal endpoints for preoperative checkpoint inhibitor trials in GU tumors are a topic of ongoing debate. While traditional endpoints such as progression-free survival (PFS) and overall survival (OS) are important, there is growing interest in using pathologic response as a surrogate endpoint of survival. Pathologic response, which measures the extent of tumor shrinkage or disappearance, has been shown to correlate with improved outcomes in several cancer types, including RCC.

Clinical management of patients with organ-confined GU tumors, such as side effect management and perioperative safety, is crucial before providing an overview of biomarker use for patient selection across the early-stage GU malignancies. Biomarkers such as PD-L1 expression and tumor mutational burden (TMB) have been shown to predict response to immunotherapy and may help guide treatment decisions.

Lastly, this book provides the reader with the most up-to-date data emerging from clinical trials involving immunotherapy in early-stage GU malignancies. These trials have demonstrated promising results in terms of response rates, PFS, and OS, and have paved the way for the integration of immunotherapy into the standard of care for these patients.

In conclusion, Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management is a comprehensive and timely resource for clinicians involved in the management of patients with localized genitourinary cancers. By providing insights into the mechanisms of response and resistance to immunotherapy, optimal trial design, clinical management, and biomarker use, this book aims to improve the outcomes and quality of life for patients with these diseases.

Weight: 516g
Dimension: 235 x 155 (mm)
ISBN-13: 9783030805487
Edition number: 1st ed. 2022